Biological Products, (No Diagnostic Substances) · DE · CIK 1357874
Precision BioSciences develops in vivo gene editing therapies using its proprietary ARCUS platform for sophisticated gene edits
Comparable business profile · signals at a glance
In the 90 days to Feb 18, 2026: 3 insiders bought $34K · 4 sold $431K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 18, 2026 | Amoroso MichaelPresident and CEO | Sell | 20,559 | $3.84 | $79K |
| Feb 18, 2026 | Kelly John AlexanderChief Financial Officer | Sell | 8,149 | $3.84 | $31K |
| Feb 18, 2026 | Scimeca DarioGeneral Counsel and Secretary | Sell | 4,925 | $3.84 | $19K |
| Feb 18, 2026 | Smith J. JeffersonChief Research Officer | Sell | 4,925 | $3.84 | $19K |
| Jan 22, 2026 | Amoroso MichaelPresident and CEO | Sell | 34,799 | $4.17 | $145K |
| Jan 21, 2026 | Kelly John AlexanderChief Financial Officer | Sell | 15,213 | $4.03 | $61K |
| Jan 21, 2026 | Smith J. JeffersonChief Research Officer | Sell | 10,200 | $4.03 | $41K |
| Jan 21, 2026 | Scimeca DarioGeneral Counsel and Secretary | Sell | 8,854 | $4.03 | $36K |
| Dec 16, 2025 | Germano Geno JDirector | Buy | 3,000 | $4.72 | $14K |
| Dec 16, 2025 | Frankel StanleyDirector | Buy | 2,700 | $4.70 | $13K |
| Dec 15, 2025 | Brown MelindaDirector | Buy | 1,381 | $4.97 | $7K |
| Nov 3, 2025 | Amoroso MichaelPresident and CEO | Sell | 3,409 | $6.49 | $22K |
| Nov 3, 2025 | Kelly John AlexanderChief Financial Officer | Sell | 1,303 | $6.49 | $8K |
| Nov 3, 2025 | Scimeca DarioGeneral Counsel and Secretary | Sell | 665 | $6.49 | $4K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.